For the past twenty years, David has been supporting biotech, medtech and pharmaceutical companies in Belgium on their M&A and financing transactions as they search for innovation and growth opportunities. During this time, he has seen his clients grow from initial venture capital backed start-ups into Euronext-listed companies and even Nasdaq successes.
With almost 20 years of extensive sector experience, David specialises in every aspect of corporate transactional work, such as public and private M&As, venture capital transactions, general corporate lending, public offerings and general company law.
He has been consistently recommended in the legal directories for corporate M&A, where the corporate team is described as “without hesitation: excellent” and David himself being noted for “excelling at creating efficient solutions to complex problems”.
David and his team work with some of the biggest pharma and biotech companies and investors in the market. These include Bone Therapeutics, TiGenix, Gilde Healthcare, Takeda Ventures, Acutus Medical, Nevro and Novo Nordisk. Recent work highlights include advising TiGenix on its NASDAQ IPO and subsequent €520 million sale to Takeda, advising Bone Therapeutics on its €10 million PIPE with European and U.S. investors and advising Gilde Healthcare on its successful investment in Nyxoah.
David joined Osborne Clarke as a Partner in 2013. He obtained his law degree from the KU Leuven (2001) and an LL.M at King’s College London (2003). In January 2021, David took over as Managing Partner of the Brussels office where he continues to head the Corporate practice.
David is a regular speaker at national and regional events in Belgium, including the annual life sciences conference ‘Knowledge for Growth’, organised by flanders.bio which hosts over 1,000 attendees each year.
He also regularly contributes articles and commentaries on company law to the leading Belgian legal journal Revue de Droit Commercial Belge/Tijdschrift voor Belgisch Handelsrecht.
Osborne Clarke advises Alpha Foods on the sale to Vendis Capital backed Sylphar, read more
Advised Infosys on a strategic partnership with ABN AMRO, including the acquisition of a majority-stake in Stater.
Assisted Belgian biotech TiGenix on its NASDAQ IPO.
Advising the group Onepoint on its public takeover bid on Vision IT Group.
On 28 April 2020, the Belgian Parliament proclaimed an act transposing Directive (EU) 2017/828 - also known as the second...
In Belgium, all Belgian companies, (I)NPOs, foundations, trusts and similar legal entities are under an obligation to register their ultimate...
Considerations and best practices for Belgian listed biotech companies when assessing and disclosing inside information (Part 4)
Good practices recommended by the Belgian Financial Services and Markets Authority (FSMA)
Considerations and best practices for Belgian listed biotech companies when assessing and disclosing inside information
What are the best practices for biotech companies in relation to inside information and the Belgian Financial Services and Markets...
Considerations and best practices for Belgian listed biotech companies when assessing and disclosing inside information (Part 2)
How does the Belgian Financial Services and Markets Authority (FSMA) determine what qualifies as inside information for biotech companies?
The Law of 20 December 2020 amends the Belgian Code on Companies and Associations (BCCA) in order to facilitate remote...
Reimbursement for patients' app purchases is important next step for rollout of the mHealthBelgium platform